#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant fibrous histiocytoma Hyperadrenocorticism Muscular dystrophy Primary amyloidosis Bile acid synthesis disorder Diffuse large B-cell lymphoma Extra-osseous Ewing's sarcoma metastatic Stress cardiomyopathy Choroidal dystrophy Henoch-Schonlein purpura nephritis Lennox-Gastaut syndrome Alagille syndrome Oesophageal adenocarcinoma Peritoneal neoplasm Vernal keratoconjunctivitis More trials…

    Learn about Rare Diseases

    Bronchiolitis obliterans syndrome – Treatment Cytokine release syndrome – Trials in Disease Hepatic angiosarcoma – Treatment Hereditary optic atrophy – Diagnostics Hairy cell leukaemia recurrent – Treatment Pulmonary fibrosis – Diagnostics Acquired haemophilia – Trials in Disease Angiosarcoma Thrombotic thrombocytopenic purpura – Trials in Disease Waldenstrom’s macroglobulinaemia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [18F]Fluoro-Peg-Folate Ima203Cd8 Atorvastatin Stiripentol Tinlarebant Cat Epithelia Cerebrolysin Concentrate Autologous Pancreatic Islets Risdiplam Medi0618 Esketamine Nazartinib ALKYLATING AGENTS RIVASTIGMINE Sulpiride Cft1946 BENZYDAMINE HYDROCHLORIDE Azd9550 Mps-102 Kan-101 More therapies…

    Learn about Your Condition

    Acute myocardial infarction Senile dementia Overweight Infertility male Fracture infection Graft versus host disease Prodromal Alzheimer's disease Varicella Hypopituitarism Primary hypogonadism Pleomorphic liposarcoma Coma Nodal osteoarthritis Lumbosacral radiculopathy Stress More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Soft Tissue Sarcoma Patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dacarbazine Citrate
    • Doxorubicin
    • Ifosfamide
    France

  • Study on Mifamurtide with Chemotherapy for Patients with High-Risk Osteosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteosarcoma
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Mifamurtide
    • Cisplatin
    • Doxorubicin Hydrochloride
    France

  • Study on the Effects of Acetylsalicylic Acid and Atorvastatin in Patients with Castration-Resistant Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Atorvastatin
    Czechia France

  • Study of Fluoroestradiol F-18 and Biomarkers for Women with ER-Positive HER2-Negative Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Fluoroestradiol F-18
    France

  • Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

    Recruiting

    2 1 1
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Belgium France Germany The Netherlands Spain Sweden

  • Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell cancer of the renal pelvis and ureter
    Investigated Drugs:
    • Enfortumab Vedotin
    • Sacituzumab Govitecan
    • Avelumab
    France Germany Greece Italy Spain

  • Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Favezelimab
    • Lenvatinib
    • Olaparib
    Austria Belgium Czechia Denmark Estonia Finland +15

  • Study on Preventing Blood Clots in Patients with Advanced Germ Cell Tumors Using Cisplatin and a Drug Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Testicular germ cell tumour
    Investigated Drugs:
    • Tinzaparin Sodium
    • Dalteparin Sodium
    • Enoxaparin Sodium
    France

  • Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

    Recruiting

    3 1 1
    Investigated Drugs:
    • Darolutamide
    Belgium France Germany Ireland Italy The Netherlands +4
Previous Page
1 … 6 7 8 9 10 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!